LOCK-IPF: Longitudinal Changes in Serum KL-6 in IPF

Upcoming study
Expected to open February 2021
This study is currently recruiting
Expected to close December 2024
This study is closed
This study closed in December 2024
We will update this page with study results when available.
Information on study results are included below
This study closed in December 2024
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

There are currently limited tests that can predict disease progression for people living with IPF and limited understanding of what the response to treatment will be like for each individual.

A molecule in the blood, called Krebs von den Lungen-6 (KL-6) is higher in people that have IPF, compared to those who do not have the disease. It is unclear, if blood levels of KL-6 change over time in people with IPF or in response to treatment with antifibrotics.

This study aims to monitor blood levels of KL-6 over 12 months in people who are newly diagnosed with IPF. This will help to understand whether KL-6 changes in relation to treatment with antifibrotics and/or progression of IPF.


What is involved?

You will be asked to have blood tests, which will look at the levels of KL-6 in your blood. Lung function tests, symptoms and antifibrotic treatment will be recorded at different time points over 12 months

Summary of involvement

Blood tests

Lung function tests

Can I take part?

You may be able to take part if you have a diagnosis of IPF and are aged 18 years and over.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the research team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Over the age of 18 years old

Confirmed multi-disciplinary team diagnosis of IPF

You will not be able to join the study of any of the following applies:

Another significant respiratory condition that is not IPF

Current smoker or smoked within the last 4 weeks

Respiratory tract infection within the last 4 weeks

Long term use of oral corticosteroids or immunosuppression within the last 4 weeks

Current participation in other research

Specific lung function criteria which will be assessed by the research team

What difference could taking part make?

Taking part in this study will help researchers to gain a better understanding of KL-6 level in the blood of people with IPF over time.

Where does the study take place?

Study locations

Manchester University Hospitals NHS Foundation Trust

How to take part

Please speak to your healthcare team if you are interested in taking part..

Further information

This page is a summary which provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Manchester University NHS Foundation Trust
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org